Investor Presentaiton

Innovation: four focused therapeutic areas Two thirds of our development portfolio comes from infectious disease and HIV Infectious Diseases RSV OA¹ MenABCWY bepirovirsen gepotidacin tebipenem Pneumococcal 24-valent mRNA influenza HIV Apretude N6LS (bNAb)² 3rd generation INSTI³ Capsid inhibitor Immunology/ Respiratory depemokimab Nucala (COPD)4 GSK4532990 (NASH)5 Oncology momelotinib Jemperli cobolimab CD226 axis Strategic business development Note: select pipeline programmes shown. 1. Respiratory syncytial virus in older adults 2. Broadly neutralising antibody 3. Integrase strand transfer inhibitor 4. Chronic obstructive pulmonary disease 5. Non-alcoholic steatohepatitis GSK 10

View entire presentation